A61K 9/1635
Obtained by reactions only involving carbon-to-carbon unsaturated bonds
Official title: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
A61K9/1635 (Obtained by reactions only involving carbon-to-carbon unsaturated bonds) appears on 1,609 US grants and 2,896 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,609
- Published applications
- 2,896
- Assignees
- 1,181
- Inventors
- 5,245
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 2 | 0 |
| 1978 | 3 | 0 |
| 1979 | 2 | 0 |
| 1980 | 3 | 0 |
| 1981 | 1 | 0 |
| 1982 | 4 | 0 |
| 1983 | 2 | 0 |
| 1984 | 3 | 0 |
| 1985 | 4 | 0 |
| 1986 | 5 | 0 |
| 1987 | 4 | 0 |
| 1988 | 10 | 0 |
| 1989 | 8 | 0 |
| 1990 | 10 | 0 |
| 1991 | 9 | 0 |
| 1992 | 13 | 0 |
| 1993 | 9 | 0 |
| 1994 | 10 | 0 |
| 1995 | 14 | 0 |
| 1996 | 16 | 0 |
| 1997 | 10 | 0 |
| 1998 | 26 | 0 |
| 1999 | 37 | 0 |
| 2000 | 27 | 0 |
| 2001 | 30 | 17 |
| 2002 | 35 | 60 |
| 2003 | 47 | 100 |
| 2004 | 25 | 109 |
| 2005 | 24 | 105 |
| 2006 | 25 | 90 |
| 2007 | 18 | 120 |
| 2008 | 22 | 102 |
| 2009 | 18 | 117 |
| 2010 | 46 | 112 |
| 2011 | 36 | 111 |
| 2012 | 59 | 106 |
| 2013 | 73 | 119 |
| 2014 | 94 | 129 |
| 2015 | 80 | 148 |
| 2016 | 70 | 149 |
| 2017 | 86 | 138 |
| 2018 | 85 | 102 |
| 2019 | 66 | 126 |
| 2020 | 68 | 150 |
| 2021 | 67 | 131 |
| 2022 | 64 | 134 |
| 2023 | 69 | 147 |
| 2024 | 66 | 105 |
| 2025 | 66 | 87 |
| 2026 | 38 | 82 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Pharmaceutical composition and method for enhancing solubility of poorly soluble active pharmaceutical ingredients15 Sep 2026US 12,734,130 B2Merck Patent GmbH
- Treatment of prostate cancer with a combination of abiraterone acetate, niraparib tosylate monohydrate and prednisone15 Sep 2026US 12,734,180 B2Janssen Pharmaceutica NV
- Compositions and methods for oral delivery of crystalline Triapine1 Sep 2026US 12,723,026 B2Nanopharmaceutics, Inc.
- Thromboxane receptor antagonist formulations18 Aug 2026US 12,708,607 B2Atxa Therapeutics Limited
- Amorphous kinase inhibitor formulations and methods of use thereof18 Aug 2026US 12,708,617 B2Deciphera Pharmaceuticals, LLC
- Subcutaneous peptide delivery system8 Oct 2026US 2026/0306408 A1
- Drug-containing particle8 Oct 2026US 2026/0306409 A1Towa Pharmaceutical Co., Ltd.
- Oral pharmaceutical formulations containing 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives8 Oct 2026US 2026/0306514 A1Cadrenal Therapeutics, Inc.
- Pharmaceutical composition comprising ibuprofen1 Oct 2026US 2026/0294855 A1
- Solid dispersion of p2x4 inhibitor, and preparation method therefor and use thereof24 Sep 2026US 2026/0284010 A1Wuhan Createrna Science and Technology Co., Ltd.
Most cited
By later US patents
- Anti-angiogenic compositions and methods of use968US 5,716,981 AAngiogenesis Technologies, Inc. · 1998
- Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers896US 5,410,016 ABoard of Regents, The University of Texas System · 1995
- Biodegradable injectable nanoparticles724US 5,543,158 AMassachusetts Institute of Technology · 1996
- Controlled release powder and process for its preparation660US 5,354,556 AElan Corporation, plc · 1994
- Gels for encapsulation of biological materials587US 5,858,746 ABoard of Regents, The University of Texas System · 1999